Sonnet BioTherapeutics Enters Licensing Agreement With Alkem Laboratories For Development And Commercialization Of SON-080 In India For Diabetic Peripheral Neuropathy
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics has entered a licensing agreement with Alkem Laboratories for the development and commercialization of SON-080 in India, targeting diabetic peripheral neuropathy. Sonnet will receive $1M upfront, up to $1M in milestone payments, and low double-digit royalties on net sales. Alkem will fund and commercialize SON-080 for chemotherapy-induced and autonomic neuropathy in India, with the market expected to grow significantly by 2030.
October 09, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics has secured a licensing agreement with Alkem Laboratories for SON-080 in India, receiving $1M upfront, potential milestone payments, and royalties. This deal could enhance Sonnet's revenue streams as the market for neuropathy treatments in India is projected to grow.
The licensing agreement provides Sonnet with immediate financial benefits and potential future revenue through milestone payments and royalties. The growing market for neuropathy treatments in India further supports a positive outlook for Sonnet's financial performance.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90